RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Immunoglobulin A Nephropathy: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Mapping the complement-targeted landscape in igA nephropathy: a systematic review with structured descriptive synthesis
Li X et al. (19 October 2026)
https://europepmc.org/search?query=Mapping%20the%20complement-targeted%20landscape%20in%20igA%20n
- 2.
Safety and efficacy of prednisolone, mizoribine and lisinopril combination therapy for severe childhood IgA nephropathy.
Shima Yuko et al., Clinical and experimental nephrology (17 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42891897/
- 3.
Clinicopathological characteristics and pedigree analysis of patients with coexisting Alport syndrome and immunoglobulin A nephropathy
Yin Ding et al., European journal of medical research (16 October 2026)
https://doi.org/10.1186/s40001-026-05360-2
- 4.
From therapeutic lag to clinical trials: the changing landscape of pediatric IgA nephropathy.
Cambier Alexandra et al., Pediatric nephrology (Berlin, Germany) (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42886355/
- 5.
Gd-IgA1 level and long-term kidney outcomes in IgA nephropathy: A systematic review and meta-analysis
Joel Iff et al., Rare Kidney Diseases (15 October 2026)
https://doi.org/10.1007/s44531-026-00013-3
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
NCT07541287 · Recruiting · Phase 2 · Jade Biosciences, Inc.
Ages 18 to 60
https://clinicaltrials.gov/study/NCT07541287
- 2.
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
NCT06994845 · Recruiting · Phase 3 · Novartis Pharmaceuticals
Ages 2 to 18
https://clinicaltrials.gov/study/NCT06994845
- 3.
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359 · Recruiting · Phase 2 · ADARx Pharmaceuticals, Inc.
Ages 18 and over
https://clinicaltrials.gov/study/NCT06989359
- 4.
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT06858319 · Recruiting · Phase 3 · Novartis Pharmaceuticals
Ages 18 to 100
https://clinicaltrials.gov/study/NCT06858319
- 5.
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827 · Recruiting · Phase 3 · Takeda
Ages 18 and over
https://clinicaltrials.gov/study/NCT06963827
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Immunoglobulin A Nephropathy
Immunoglobulin A nephropathy is a kidney disease in which deposits of the antibody IgA build up in the filtering units of the kidneys and cause inflammation. It often shows up as blood in the urine, protein in the urine or high blood pressure, and it can slowly reduce kidney function over many years. Management includes blood pressure control, medicines that reduce protein loss, and in some cases treatments that dampen the immune system.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Immunoglobulin A Nephropathy?
Immunoglobulin A nephropathy is a kidney disease in which deposits of the antibody IgA build up in the filtering units of the kidneys and cause inflammation. It often shows up as blood in the urine, protein in the urine or high blood pressure, and it can slowly reduce kidney function over many years. Management includes blood pressure control, medicines that reduce protein loss, and in some cases treatments that dampen the immune system.
How many clinical trials are available for Immunoglobulin A Nephropathy?
RareWays currently indexes 205 clinical trials for Immunoglobulin A Nephropathy, of which 45 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Immunoglobulin A Nephropathy come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Immunoglobulin A Nephropathy.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.